In silico data mining of large-scale databases for the virtual screening of human interleukin-2 inhibitors.

Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences
Sobia Ahsan HalimAhmed Al-Harrasi

Abstract

Interleukin-2 (IL-2) is involved in the activation and differentiation of T-helper cells. Uncontrolled activated T cells play a key role in the pathophysiology by stimulating inflammation and autoimmune diseases like arthritis, psoriasis and Crohn's disease. T cells activation can be suppressed either by preventing IL-2 production or blocking the IL-2 interaction with its receptor. Hence, IL-2 is now emerging as a target for novel therapeutic approaches in several autoimmune disorders. This study was carried out to set up an effective virtual screening (VS) pipeline for IL-2. Four docking/scoring approaches (FRED, MOE, GOLD and Surflex-Dock) were compared in the re-docking process to test their performance in producing correct binding modes of IL-2 inhibitors. Surflex-Dock and FRED were the best in predicting the native pose in its top-ranking position. Shapegauss and CGO scoring functions identified the known inhibitors of IL-2 in top 1, 5 and 10 % of library and differentiated binders from non-binders efficiently with average AUC of > 0.9 and > 0.7, resp. The applied docking protocol served as a basis for the VS of a large database that will lead to the identification of more active compounds against IL-2.

References

Apr 4, 1997·Journal of Molecular Biology·G JonesR Taylor
Dec 29, 2000·Journal of Computer-aided Molecular Design·G M VerkhivkerP W Rose
Apr 12, 2001·Journal of Medicinal Chemistry·M Stahl, M Rarey
Feb 23, 2002·Bioorganic & Medicinal Chemistry Letters·Bolin GengPeter V Pallai
May 23, 2002·Transplantation·Alain Le MoineDaniel Abramowicz
Jan 25, 2003·Journal of Molecular Graphics & Modelling·Jonas BoströmJohan Gottfries
Feb 13, 2003·Biopolymers·Mark R McGannFrank K Brown
Feb 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Michelle R ArkinAndrew C Braisted
Feb 18, 2003·QJM : Monthly Journal of the Association of Physicians·A C Church
Mar 27, 2003·Journal of the American Chemical Society·Andrew C BraistedBrian C Raimundo
Dec 11, 2003·Journal of the American Chemical Society·Christopher D ThanosJames A Wells
Apr 3, 2004·Nature Reviews. Drug Discovery·Michelle R Arkin, James A Wells
Oct 12, 2004·Cytokine·Sarah L Gaffen, Kathleen D Liu
Jan 26, 2005·Journal of Chemical Information and Modeling·John J Irwin, Brian K Shoichet
Feb 3, 2005·Bioorganic & Medicinal Chemistry Letters·Nathan D WaalBrian C Raimundo
Apr 29, 2005·Journal of Medicinal Chemistry·Yvonne C Martin
Jun 27, 2007·Journal of Chemical Information and Modeling·Georgia B McGaugheyWendy D Cornell
Oct 16, 2007·Current Opinion in Chemical Biology·Campbell McInnes
May 8, 2010·Journal of Molecular Graphics & Modelling· Zaheer-ul-HaqJeffry D Madura
Jul 28, 2010·Chemical Biology & Drug Design·M Ahmed MesaikAqeel Ahmad
Dec 21, 2011·Chemical Biology & Drug Design·M Ahmed MesaikM Iqbal Choudhary
Mar 16, 2013·Molecular Diversity·Sobia Ahsan HalimMaria Kontoyianni
Aug 9, 2015·Computational Biology and Chemistry·Sobia Ahsan HalimTayyab Husnain
May 1, 1999·Journal of Computational Chemistry·Thomas A Halgren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.